Pacific Biosciences of California, Inc. — Cyborg Score 3/10
Challenged
Biotechnology / Life Sciences Instrumentation
Strategic Profile
Pacific BioSciences of California was founded in 2004. The company operates in genomics sequencing instrumentation with products used in research and emerging clinical applications. However, the company faces significant financial challenges including substantial operational losses and declining revenue growth.
Cyborg Score Rationale
A mere glance at Pacific Biosciences' income statement reveals total revenue hitting $38.44 million and grappling with a loss of $38 million from continuous operations. Its EBIT margin shows an even more concerning -320.4%. As of now, Pacific Biosciences has an alarming free cash flow standing at -$18.62M, aggravated by intensified R&D commitments that strain their balance.
Top Insights
On Tuesday, February 17, 2026 Pacific Biosciences of California Inc. stock [NASDAQ: PACB] is trending down by -8.48%.
With revenue standing at a modest $38.44M for the last quarter, the figures indicate a clear struggle to maintain previous earnings highs. A concerning element emerges as total expenses swell to $54.78M, pushing the company's financials into turbulent waters.
Pacific Biosciences faces intense and mounting pressure from its semiconductor counterparts—companies eager to scoop up market share with lucrative AI-powered endeavors.
A strategic partnership with a leading genomics firm promises to enhance research and development capacities. These alliances are seen as critical for making strides in their target markets, such as sequencing technology and diagnostics.
Named Competitors
Illumina Platform — Market leader in DNA sequencing and genomic analysis